New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

CD47 (Extracellular region) Antibody

Applications

  • WB
  • IP
  • ICC

Reactivity

  • Human
Overview
Catalog # bsm-70414M
Product Name CD47 (Extracellular region) Antibody
Applications WB, IP, ICC
Specificity Clone M054 mouse monoclonal antibody detects native human CD47, as well as aldehyde-fixed CD47. The antibody works for staining in immunocytochemistry, capture and detection in ELISA, native immunoprecipitation and western blot. The antibody detects a 45 to 55 kDa band in native western blots of A431, BEAS-2B, MCF7, NCI-H446, NCI-H28, and NCI-H2052 cell lines.
Reactivity Human
Specifications
Conjugation Unconjugated
Host Mouse
Source Clone (M054) was generated from a recombinant protein that included the extracellular region of human CD47 protein.
Clonality Monoclonal
Clone # M054
Isotype IgG1
Purification Purified by Protein G.
Storage Buffer PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol
Storage Condition Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Target
Swiss Prot Q08722
Synonyms Antigenic surface determinant protein OA3, Integrin-associated protein, IAP, Leukocyte surface antigen CD47, MER6
Background CD47 is a five-pass transmembrane protein expressed on all normal cells, as well as in cancer cells. CD47 is used by macrophages to distinguish between "self" and "non-self" cells. SIRPα expressed on myeloid cells including macrophages, and neuronal cells in the central nervous system, can bind CD47. SIRPα cytoplasmic tail can inhibit macrophage phagocytosis towards CD47-expressing cells. Thus, the CD47/SIRPα pahtway serves as an innate immune checkpoint. Additionally, CD47 was reported to modulate lymphocyte cell activation and proliferation. CD47 is over-expressed in many types of cancer, and the expression level of CD47 on cancer cells is negatively associated with cancer survival. Monoclonal antibody therapies that can block CD47-SIRPα interaction are being actively pursued for clinical applications. In addition to SIRPα, CD47 interacts with thrombospondin-1, VEGFR2, FAS, and certain integrins in different contexts, and influences their downstream signaling.
Application Dilution
WB 1:300-5000
IP 1-2ug
ICC 1:100-500